Ruth Karron, MD
- Director, Center for Immunization Research
- Director, Johns Hopkins Vaccine Initiative
- Division: Global Disease Epidemiology and Control
Center & Institute Affiliations
624 N. Broadway
Hampton House 217
Baltimore, Maryland 21205
MD, New York University, 1982
I am trained in pediatric infectious diseases and virology and have a particular interest in respiratory viruses and respiratory virus vaccines. At the Center for Immunization Research, we conduct a large number of phase I and II trials of respiratory virus vaccines in adults and children as young as one month of age. In our laboratory, we conduct studies to determine how the immune response to respiratory viruses matures over the life span, with a particular focus on the differences between very young infants and older children. We are also involved in studies of RSV (respiratory syncytial virus) pathogenesis, to determine host and viral factors that may contribute to severe disease. Finally, we are also interested in the epidemiology of respiratory virus infections in resource-poor settings.
- International Health Disease Control CIR Vaccine development respiratory viruses influenza RSV parainfluenza immunity
Selected publications: Karron RA, Wright PF, Newman FK, Makhene M, Thompson J, Samorodin R, Wilson MH, Anderson EA, Clements ML, Murphy BR, Belshe RB. A live human parainfluenza type 3 virus vaccine is attenuated and immunogenic in healthy infants and children. J Infect Dis 1995;172: 1445-50.
Clements ML, Makhene MK, Karron RA, Murphy BR, Steinhoff MC, Subbarao K, Wilson MH, the Pediatric Care Center, Wright PF. Effective immunization with live attenuated influenza A virus can be achieved in early infancy. J Infect Dis 1996;173:44-51.
Karron RA, Makhene M, Gay K, Wilson MH, Clements ML, Murphy BR. Evaluation of a live attenuated bovine parainfluenza type 3 vaccine in 2-to-6-month-old infants. Ped Infect Dis J 1996; 15: 650-4.
Karron RA, Wright PF, Crowe JE Jr, Clements ML, Thompson J, Makhene M, Casey R, Murphy BR. Evaluation of two live, cold-passaged, temperature-sensitive respiratory syncytial virus (RSV) vaccines in chimpanzees, adults, infants and children. J Infect Dis 1997;176:1428-37.
Karron RA, Buonagurio DA, Georgiu AF, Whitehead SS, Adamus JE, Clements-Mann ML, Harris DO, Randolph VB, Udem SA, Murphy BR, Sidhu MS. Respiratory syncytial virus SH and G proteins are not essential for viral replication in vitro: clinical evaluation and molecular characterization of a cold-passaged, attenuated RSV subgroup B mutant. Proc Natl Acad Sci 1997; 94:13961-66.